ArticleBMC ophthalmology2026
Construction of a prediction model for the early efficacy of 577-nm-SML in treating CSC based on Bayesian network.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCentral Serous Chorioretinopathy(CSC) is a chorioretinal disorder, predominantly affects young to middle-aged adults, resulting serious vision disorder. This study aimed to develop a Bayesian network model to predict the key factors influencing the early therapeutic efficacy of 577 nm-SML in patients with CSC.
methodsA total of 159 patients (159 eyes) diagnosed with CSC and treated with 577 nm-SML at the First Affiliated Hospital of Guangxi Medical University from January 2019 to November 2023 were retrospectively analyzed. Baseline data including age, sex, eye side, disease course, and past medical history were collected. Ophthalmic imaging detects central macular thickness (CMT), macular foveal volume (MFV within 1mm, 3mm, 6mm diameter), height and area of subretinal fluid (SRF), structural changes in the outer retinal layers (ORL), type and area of leakage lesions, etc. Influential variables significantly associated with 577nm-SML efficacy were screened using LASSO regression, then construct a Bayesian network model to predict factors that significantly affect the therapeutic effect.
resultsLASSO regression identified 19 significant variables related to treatment outcomes from the 40 possible risk factors included, including disease duration, sex, eye Side, smoking, hormone, macular foveal volumes (3 mm and 6 mm diameters), and the height and area of SRF, ORL integrity, typical PED, location of PED, location of RPE bulging, heterogeneity of NPL, HF of ORL, HF of choroid, leakage type, leakage location, leakage correlate with OCT. The Bayesian network presents complex interactions among these factors, shows that patients with smaller macular foveal volumes (within 3 mm diameter), shorter disease duration, and focal leakage exhibited superior responses to 577nm-SML treatment.
conclusionThe therapeutic response to 577nm-SML in CSC is influenced by multifactorial dynamics. Bayesian network can well present the complex network relationship between the therapeutic effect of 577nm-SML and related influencing factors, and identify potential risk factors that affect early efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.